Woodline Partners LP Uni Qure N.V. Transaction History

Woodline Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $1.12 Million - $2.24 Million	-100,989 Reduced 59.16%	69,721 $799,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $3.19 Million - $3.94 Million	170,710 New	170,710 $3.44 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $2.94 Million - $5.43 Million	-73,405 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $2.73 Million - $5.48 Million	73,405 New	73,405 $5.26 Million

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.